文献速递妇科肿瘤

尼拉帕利单药新辅助治疗不可切除HRD阳性高级别浆液性卵巢癌的II期研究

Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2026-10-07

NANT研究是一项在中国六家三级医院开展的单臂II期试验,评估尼拉帕利单药新辅助治疗初始不适合初次减瘤术的HRD阳性晚期高级别浆液性/子宫内膜样卵巢癌。67例入组患者中,可评估疗效者客观缓解率为63%(95%CI 47-76),手术患者R0切除率为80%(95%CI 64-91)。结论认为该无化疗方案在特定患者中显示抗肿瘤活性并使R0切除可行,但仍属研究性,需随机对照验证。

要点

  • HRD阳性晚期卵巢癌中,尼拉帕利新辅助单药ORR达63%(95%CI 47-76)。
  • 手术患者R0切除率为80%(95%CI 64-91)。
  • 3-4级治疗相关不良事件以血小板减少(48%)最常见,无治疗相关死亡。

核心结论

  • 新辅助尼拉帕利单药在初始不适合初次减瘤术的HRD阳性晚期卵巢癌患者中显示抗肿瘤活性,并使部分患者获得R0切除。
  • 该策略仍属研究性,需与标准铂-紫杉类新辅助化疗进行随机对照验证。

研究设计与样本

  • 多中心、单臂、II期试验,在中国六家三级医院开展。
  • 入组67例初治、FIGO III-IV期、HRD阳性高级别浆液性或子宫内膜样卵巢癌患者,按预设标准判断初次减瘤术完全切除可能性低。
  • 患者接受两个28天周期的口服尼拉帕利单药治疗,起始剂量个体化为200 mg或300 mg。
  • 共同主要终点为疗效可评估人群的研究者评估客观缓解率和手术人群的R0切除率。

主要发现

  • 48例疗效可评估患者中30例获客观缓解,客观缓解率63%(95%CI 47-76)。
  • 40例手术患者中32例达R0切除,R0切除率80%(95%CI 64-91)。
  • 3-4级治疗相关不良事件最常见为血小板减少32例(48%)、白细胞减少13例(19%)、贫血12例(18%)、中性粒细胞减少9例(13%)。
  • 严重不良事件发生于19例(28%)患者,无治疗相关死亡。

临床怎么用

  • 对初始不适合初次减瘤术的HRD阳性晚期高级别浆液性卵巢癌,尼拉帕利单药新辅助可作为研究性选择,尚不能替代标准铂-紫杉类新辅助化疗。
  • 治疗期间需重点监测血小板减少等血液学毒性。

局限性

  • 单臂设计、无对照组,结论需随机对照试验验证。
  • 疗效可评估人群(48例)与手术人群(40例)小于总入组67例,存在选择偏倚可能。
  • 全部入组患者为汉族女性,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant chemotherapy followed by interval debulking surgery is standard treatment for advanced ovarian cancer that is unlikely to achieve optimal cytoreduction. We aimed to evaluate a chemotherapy-free regimen of neoadjuvant niraparib monotherapy in homologous recombination deficiency (HRD)-positive disease initially unsuitable for primary debulking surgery. METHODS: This single-arm, phase 2 trial was conducted at six tertiary hospitals in China. Eligible patients were aged 18-75 years, had treatment-naïve, FIGO stage III-IV HRD-positive high-grade serous or endometrioid ovarian cancer, an ECOG performance status of 0-2, with a low likelihood of complete primary debulking surgery based on prespecified criteria. Patients received oral niraparib monotherapy for two 28-day cycles with an individualised starting dose of 200 mg or 300 mg. Protocol-permitted supportive care was provided as clinically indicated. Co-primary endpoints were investigator-assessed objective response rate in the response-evaluable population and R0 resection rate after interval debulking surgery in the operated population. Safety was assessed in all patients who received at least one dose of niraparib. The trial was registered with ClinicalTrials.gov (NCT04507841), is closed to enrolment, and this report presents the primary analysis. FINDINGS: Between Jan 8, 2021, and Jul 18, 2023, 127 patients were screened, and 67 were enrolled into the study. All enrolled patients were female and self-identified as Han Chinese (median age 55 years [IQR 50-62]). At the data cutoff (Dec 29, 2025), median follow-up was 37·7 months (IQR 31·8-48·5). Among 48 response-evaluable patients, 30 achieved an objective response, with an objective response rate of 63% (95% CI 47-76). Among 40 operated patients, 32 achieved R0 resection, with an R0 resection rate of 80% (95% CI 64-91). The most common grade 3-4 treatment-related adverse events were thrombocytopenia in 32 (48%) of 67 patients, leukopenia in 13 (19%) patients, anaemia in 12 (18%) patients, and neutropenia in nine (13%) patients. Serious adverse events occurred in 19 (28%) patients. No treatment-related deaths occurred. INTERPRETATION: Neoadjuvant niraparib showed anti-tumour activity and enabled R0 resection in selected patients with HRD-positive advanced ovarian cancer who were initially unsuitable for primary debulking surgery. This strategy remains investigational and requires randomised validation against standard platinum-taxane neoadjuvant chemotherapy. FUNDING: National Key Technology Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Hubei Province, Innovative Drug Research and Development National Science and Technology Major Project, and Zai Lab (Shanghai). TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Liu D, Peng Z, Zhang W, et al. Neoadjuvant niraparib monotherapy for unresectable, homologous recombination deficiency-positive, high-grade serous ovarian cancer (NANT): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2026. PMID: 42843394. doi:10.1016/S1470-2045(26)00387-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。